No man, RS 1:500 first then 1:10,000
On September 19, 2018, Seamus Lagan, Chief Executive Officer and President of Rennova Health, Inc. (the “Company”), and Alcimede LLC, of which Mr. Lagan is the sole manager, the holders of 26,684,380 shares of common stock and 250,000 shares of Series J Convertible Preferred Stock (the “Series J Preferred Stock”), which votes with the common stock and the Series F Convertible Preferred Stock (the “Series F Preferred Stock”), with each share of Series J Preferred Stock having 12,000 votes, representing 50.4% of the total voting power of the Company’s voting securities, approved by written consent in lieu of a special meeting of stockholders the following proposal, which had previously been approved and recommended to be approved by the stockholders by the Board of Directors of the Company.
Proposal 1 : To approve an amendment to our Certificate of Incorporation, as amended, to effect a reverse stock split of all of the outstanding shares of our common stock, at a specific ratio from 1-for-100 to 1-for-10,000, and to grant authorization to our Board of Directors to determine, in its discretion, the specific ratio and timing of the reverse split any time before September 30, 2019, subject to the Board of Directors’ discretion to abandon such amendment.
The stockholder approval of the above proposal will not be effective until 20 days after an information statement that has been filed with the Securities and Exchange Commission is mailed to the holders of our common stock, Series F Preferred Stock and Series J Preferred Stock. The above proposal is separate from, and in addition to, the authorization of a reverse split of our common stock at a specific ratio from 1-for-200 to 1-for-500 previously approved by our Board of Directors and stockholders on August 21, 2018 and August 22, 2018, respectively. The stockholder approval of that proposal became effective on September 18, 2018.
